Nazanin Majd, M.D., Ph.D.

Peer-Reviewed Articles

1. Yeboa, DN, Whitfield, BT, Lin, R, Ejezie, CL, Swanson, T, Beckham, TH, Wang, C, De, BS, Perni, S, Tom, MC, Li, J, McGovern, SL, Harrison, R, Majd, NK, Puduvalli, VK, Aaroe, AE, Loghin, ME, O'Brien, BJ, Patel, AD, Patel, C, Wefel, JS, Taslicay, CA, Gule-Monroe, MK, Paulino, AC, McAleer, MF, Grosshans, DR, Ghia, AJ, Jiang, W, Chung, C, Maor, MM, Yang, CH, Gubbiotti, M, Kamiya Matsuoka, C, Ballester, L, Weathers, S, Huse, J. Prospective phase II clinical trial of molecular glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41191157.
2. Dasgupta, P, Dagher, SA, Chi, X, Soomro, Z, Bhat, S, Campbell, E, Wintermark, M, Puduvalli, VK, Lin, R, Chen, MM, Majd, NK. Genomic determinants of the diffusely infiltrative gliomatosis cerebri phenotype. Journal of neuro-oncology 176(1), 2026. e-Pub 2026. PMID: 41099968.
3. Rudneva V, Newton A, Majd NK, Magge R, Sengupta S, Goichot B, Piotrowski A, Gavrilovic I, Cooper O, Rosenblum M, Kaley T, Mellinghoff I, Young RJ, A Donoghue MT, Tabar V, Geer EB. Immune checkpoint inhibitor therapy for aggressive pituitary neuroendocrine tumors. J Clin Endocrinol Metab 110(11):3066-3073, 2025. e-Pub 2025. PMID: 40109237.
4. Dasgupta, P, Lin, Y, Kumar, G, Soomro, Z, Ayala, MM, Parra Cuentas, ER, Weathers, S, Lang Jr, FF, Bhat, KP, de Groot, JF, Majd, NK. Molecular and clinical determinants of response to checkpoint inhibitor immunotherapy in glioblastoma. Journal of neuro-oncology 175(1):453-461, 2025. e-Pub 2025. PMID: 40560330.
5. Majd N. Prospective phase II clinical trial of Molecular Glioblastoma (historical grade 2 and 3 IDH wildtype gliomas) preliminary novel exploratory analyses. Journal of Neuro-Oncology. e-Pub 2025.
6. Dasgupta P, Lin H, Kumar G, Soomro Z, Ayala MM, Parra ER, Weathers S, P Bhat FFLK, Groot J, Majd NK. Molecular and Clinical Determinants of Response to Checkpoint Inhibitor Immunotherapy in Glioblastoma. Journal of Neuro Oncology. e-Pub 2025.
7. Weathers, S, Li, X, Zhu, H, Damania, A, Knafl, M, McKinley, BA, Lin, Y, Harrison, R, Majd, NK, O’Brien, BJ, Penas-Prado, M, Loghin, ME, Kamiya-Matsuoka, C, Yung, WA, Solis Soto, LM, Maru, DM, Wistuba, II, Parra Cuentas, ER, Hernandez, S, Futreal, A, Wargo, J, Schulze, K, Darbonne, WC, Ajami, NJ, Woodman, SE, de Groot, JF. Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features. Nature communications 16(1):3950, 2025. e-Pub 2025. PMID: 40289138.
8. Frade, HC, Qasim, M, Shivaprasad, A, Fuller, GN, El-Naggar, AK, Viswanathan, A, Tremont, I, Majd, NK. Delayed Diagnosis of Amphetamine-Associated CNS Vasculitis Presenting as a Mass Lesion. Annals of Internal Medicine Clinical Cases 4(2), 2025. e-Pub 2025.
9. Pham, L, Weller, L, Gann, CN, Schumacher, K, Vlassak, S, Swanson, T, Highsmith, KN, O’Brien, BJ, Nash, S, Aaroe, AE, De Groot, J, Majd, NK. Prolonged complete response to adjuvant tepotinib in a patient with newly diagnosed disseminated glioblastoma harboring mesenchymal-epithelial transition fusion. Oncologist 30(1), 2025. e-Pub 2025. PMID: 38815166.
10. Lam, K, Nasr, L, Andersen, C, Marqueen, KE, Li, J, Wang, C, Beckham, TH, Majd, NK, Aaroe, AE, Loghin, ME, O'Brien, BJ, McGovern, SL. Early Outcomes from Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology 10(2), 2024. e-Pub 2024. PMID: 39866593.
11. Gregory, TA, Knight, SR, Aaroe, AE, Highsmith, KN, Janatpour, ZC, O’Brien, BJ, Majd, NK, Loghin, ME, Patel, C, Weathers, S, Puduvalli, VK, Kamiya Matsuoka, C. Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: A retrospective case-control study. Neuro-Oncology Practice 11(4):475-483, 2024. e-Pub 2024. PMID: 39006516.
12. Dagher SA, Liu H, Ozkara BB, Calle S, Kaya D, Gule-Monroe MK, Chasen NN, Schellingerhout D, Learned KO, Shah KB, Johnson JM, Sun J, Schomer DF, Kumar VA, Wintermark M, Majd NK, Nam JY, Chen MM. The Impact of MRI-Based Advanced Neuroimaging on Neuro-Oncologists’ Clinical Decision-Making in Patients With Post treatment High-Grade Glioma: A Prospective Survey. American Journal of Roentgenology 223(4), 2024. PMID: 39140632.
13. Pabon CM, Yeboa DN, O’Brien BJ, Majd NK, Wang C, Blum Murphy MA. Intrathecal topotecan with systemic checkpoint inhibitor therapy for gastroesophageal cancer with leptomeningeal involvement: two case reports and review of the literature. Journal of Gastrointestinal Oncology 15(3):1331-1340, 2024. e-Pub 2024. PMID: 38989402.
14. Majd NK, Vo HH, Moran CA, Weathers S, Song I, Williford GL, Rodon J, Fu S, Tsimberidou A. Metastatic extraneural glioblastoma diagnosed with molecular testing. The Oncologist 29(9):811-816, 2024. e-Pub 2024. PMID: 38837109.
15. Lin, AL, Rudneva, VA, Richards, AL, Zhang, Y, Woo, HJ, Cohen, MA, Tisnado, J, Majd, NK, Wardlaw, SL, Page-Wilson, G, Sengupta, S, Chow, F, Goichot, B, Ozer, BH, Dietrich, J, Nachtigall, L, Desai, A, Alano, T, Ogilive, S, Solit, DB, Bale, T, Rosenblum, MK, Donoghue, MT, Geer, EB, Tabar, V. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors. Acta neuropathologica 147(1), 2024. e-Pub 2024. PMID: 38758238.
16. Wang, C, Rooney, MK, Alvarez-Breckenridge, C, Beckham, TH, Chung, C, De, BS, Ghia, AJ, Grosshans, DR, Majd, NK, McAleer, MF, McGovern, SL, North, RY, Paulino, AC, Perni, S, Reddy, JP, Rhines, LD, Swanson, T, Tatsui, CE, Tom, MC, Yeboa, DN, Li, J. Outcomes and Pattern of Care for Spinal Myxopapillary Ependymoma in the Modern Era—A Population-Based Observational Study. Cancers 16(11):2013, 2024. e-Pub 2024. PMID: 38893133.
17. Dasgupta, P, Ou, A, Lin, Y, Gregory, TA, Alfaro-Munoz, KD, Yuan, Y, Afshar-Khargan, V, Kamiya Matsuoka, C, Rousseau, JF, Majd, NK. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. Journal of neuro-oncology 167(1):181-188, 2024. e-Pub 2024. PMID: 38372903.
18. Huntoon, K, Gasco, J, Glitza, IC, Ferguson, SD, Majd, NK, McCutcheon, IE. Ventriculoperitoneal shunting with an on–off valve for patients with leptomeningeal metastases and intracranial hypertension. Neuro-Oncology Practice 11(1):56-63, 2024. e-Pub 2024. PMID: 38222058.
19. Majd, NK, Yeboa, DN, Wang, S, Weathers, S, Yuan, Y, Al Anssari, H, Kamiya Matsuoka, C, O'Brien, BJ, Aaroe, AE, Patel, C, Dagher, SA, Wintermark, M, Ferguson, SD, Puduvalli, VK, Liu, SJ, Raleigh, D, de Groot, JF. Phase I clinical trial of peposertib plus radiation in adults with newly diagnosed MGMT-unmethylated glioblastoma. Journal of Clinical Oncology 42(16_suppl):2076, 2024. e-Pub 2024.
20. Harrison RA, Majd N, Johnson MO, Urbauer DL, Puduvalli VK, Khasraw M. Characterization of Industry Relationships in Oncology. Cancer 40(16):2848-2855, 2023. e-Pub 2023. PMID: 37227811.
21. Rodriguez A, Kamiya-Matsuoka C, Majd NK. The Role of Immunotherapy in the Treatment of Rare Central Nervous System Tumors. Current Oncology 30(6):5279-5298, 2023. e-Pub 2023. PMID: 37366884.
22. Gregory TA, Williford GL, Maronge JM, Alfaro K, Fuller GN, Groot J, Puduvalli VK, Ballester LY, Majd NK. An expedited strategy for accurate and timely integrated molecular diagnosis of gliomas. Neuro-Oncology 25(4):808-809, 2023. e-Pub 2023. PMID: 36723868.
23. Gregory, TA, Mastall, M, Lin, Y, Hess, KR, Yuan, Y, Martin-Bejarano Garcia, M, Fuller, GN, Alfaro, KD, Gule-Monroe, MK, Huse, J, Khatua, S, Rao, G, Sandberg, DI, Wefel, JS, Yeboa, DN, Paulino, AC, McGovern, SL, Zaky, W, Mahajan, A, Suki, D, Weathers, S, Harrison, R, De Groot, J, Puduvalli, VK, Penas-Prado, M, Majd, NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neuro-Oncology Advances 5(1), 2023. e-Pub 2023. PMID: 37114244.
24. Pushan D, Veerakumar B, de Groot JF, Majd NK. Preclinical Models of Low-Grade Gliomas. Cancers 15(3), 2023. e-Pub 2023. PMID: 36765553.
25. de Groot J, Ott M, Wei J, Kassab C, Fang D, Najem H, O'Brien BJ, Weathers SP, Kamiya Matsouka C, Majd NK, Harrison RA, Fuller GN, Huse JT, Long JP, Sawaya R, Rao G, MacDonald TJ, Priebe W, DeCuypere M, Heimberger AB. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncology 11(2):CNS87, 2022. e-Pub 2022. PMID: 35575067.
26. Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi J, Kamiya-Matsuoka C, Ballester LY. Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study. Neurosurgery 90(5):515-522, 2022. e-Pub 2022. PMID: 35179134.
27. Khan, S, Mahalingam, R, Sen, S, Martinez-Ledesma, JE, Khan, A, Gandy, K, Lang Jr, FF, Sulman, EP, Alfaro-Munoz, KD, Majd, NK, Balasubramaniyan, V, de Groot, JF. Intrinsic interferon signaling regulates the cell death and mesenchymal phenotype of glioblastoma stem cells. Cancers 13(21), 2021. e-Pub 2021. PMID: 34771447.
28. Nantavithya, C, Paulino, AC, Liao, K, Woodhouse, KD, McGovern, SL, Grosshans, DR, McAleer, MF, Khatua, S, Chintagumpala, M, Majd, NK, Zaky, W, Yeboa, DN. Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma. Cancer 127(13):2368-2375, 2021. e-Pub 2021. PMID: 33721338.
29. Majd, NK, Yap, TA, Koul, D, Balasubramaniyan, V, Li, X, Khan, S, Gandy, K, Yung, WA, de Groot, JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neuro-Oncology Advances 3(1), 2021. e-Pub 2021. PMID: 33738447.
30. Majd, NK, Mastall, M, Lin, Y, Dibaj, S, Hess, KR, Yuan, Y, Garcia, MB, Fuller, GN, Alfaro, KD, Gule-Monroe, MK, Huse, J, Khatua, S, Rao, G, Sandberg, DI, Wefel, JS, Yeboa, DN, Paulino, AC, McGovern, SL, Zaky, W, Mahajan, A, Suki, D, Weathers, S, Harriso, RA, De Groo, JF, Puduvalli, VK, Penas-Prado, M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-Oncology Advances 3(1), 2021. e-Pub 2021. PMID: 34377987.
31. Majd NK, Waguespack SG, Janku F, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza SM, McCutcheon IE, Naing A. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. Journal for Immunotherapy Cancer 8(2), 2020. e-Pub 2020. PMID: 33427689.
32. Park SY, Mittal S, Dong J, Jeong K, Martinez-Ledesma E, Piao Y, Khan S, Henry V, Verhaak RG, Majd NK, Balasubramaniyan V, De Groot JF. Depletion of CLK2 sensitizes glioma stem-like cells to PI3K/mTOR and FGFR inhibitors. American Journal of Cancer Research 10(11):3765-3783, 2020. e-Pub 2020. PMID: 33294266.
33. Ferguson SD, Hodges TR, Majd NK, Alfaro-Munoz K, Al-Holou WN, Suki D, de Groot JF, Fuller GN, Xue L, Li M, Jacobs C, Rao G, Colen RR, Xiu J, Verhaak R, Spetzler D, Khasraw M, Sawaya R, Long JP, Heimberger AB. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neuro-Oncology Advances 3(2), 2020. e-Pub 2020. PMID: 33426529.
34. Trevino CR, Paulino AC, Kumar VA, Majd N, Penas-Prado M. Radiation-induced central demyelination, report of a rare subacute complication and review of the literature. Journal Neuroimmunology and Neuroinflammation. e-Pub 2020.
35. Nantavithya C, Paulino AC, Liao K, McGovern SL, Grosshans DR, McAleer MF, Woodhouse KD, Khatua S, Chintagumpala MM, Majd NK, Yeboa DN. Development of Second Primary Tumors and Outcomes in Medulloblastoma by Treatment Modality: A Surveillance, Epidemiology, and End Results Analysis. Pediatric Blood & Cancer 67(8), 2020. e-Pub 2020. PMID: 32453481.
36. Weathers, S, Penas-Prado, M, Pei, BL, Ling, X, Kassab, C, Banerjee, PP, Bdiwi, M, Shaim, H, Alsuliman, A, Shanley, M, de Groot, JF, O'Brien, BJ, Harrison, R, Majd, NK, Kamiya Matsuoka, C, Fuller, GN, Huse, J, Chi, TL, Rao, G, Weinberg, J, Lang Jr, FF, Sawaya, RE, Shpall, E, Rezvani, K, Heimberger, AB. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clinical Cancer Research 26(14):3565-3577, 2020. e-Pub 2020. PMID: 32299815.
37. Aaroe AE, Majd NK, Weathers SP, De Groot JF. Potential neurologic and oncologic implications of the novel coronavirus. Neuro-Oncology 22(7):1050-1051, 2020. e-Pub 2020. PMID: 32296828.
38. Khan S, Mittal S, McGee K, Alfaro-Munoz KD, Majd N, Balasubramaniyan V, de Groot JF. Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. International Journal of Molecular Sciences 21(6), 2020. e-Pub 2020.
39. Kofuji S, Hirayama A, Eberhardt AO, Kawaguchi R, Sugiura Y, Sampetrean O, Ikeda Y, Warren M, Sakamoto N, Kitahara S, Yoshino H, Yamashita D, Sumita K, Wolfe K, Lange L, Ikeda S, Shimada H, Minami N, Malhotra A, Morioka S, Ban Y, Asano M, Flanary VL, Ramkissoon A, Chow LML, Kiyokawa J, Mashimo T, Lucey G, Mareninov S, Ozawa T, Onishi N, Okumura K, Terakawa J, Daikoku T, Wise-Draper T, Majd N, Kofuji K, Sasaki M, Mori M, Kanemura Y, Smith EP, Anastasiou D, Wakimoto H, Holland EC, Yong WH, Horbinski C, Nakano I, DeBerardinis RJ, Bachoo RM, Mischel PS, Yasui W, Suematsu M, Saya H, Soga T, Grummt I, Bierhoff H, Sasaki AT. IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol 21(8):1003-1014, 2019. e-Pub 2019. PMID: 31371825.
40. Yoshino H, Yin G, Kawaguchi R, Popov KI, Temple B, Sasaki M, Kofuji S, Wolfe K, Kofuji K, Okumura K, Randhawa J, Malhotra A, Majd N, Ikeda Y, Shimada H, Kahoud ER, Haviv S, Iwase S, Asara JM, Campbell SL, Sasaki AT. Identification of lysine methylation in the core GTPase domain by GoMADScan. PLoS One 14(8):e0219436, 2019. e-Pub 2019. PMID: 31390367.
41. Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leuk Lymphoma 57(7):1709-13, 2016. e-Pub 2016. PMID: 26727654.
42. Sumita K, Lo YH, Takeuchi K, Senda M, Kofuji S, Ikeda Y, Terakawa J, Sasaki M, Yoshino H, Majd N, Zheng Y, Kahoud ER, Yokota T, Emerling BM, Asara JM, Ishida T, Locasale JW, Daikoku T, Anastasiou D, Senda T, Sasaki AT. The Lipid Kinase PI5P4Kβ Is an Intracellular GTP Sensor for Metabolism and Tumorigenesis. Mol Cell 61(2):187-98, 2016. e-Pub 2016. PMID: 26774281.
43. Majd N, Sumita K, Yoshino H, Chen D, Terkawa J, Daikoku T, Curry R, Wise-Draper T, Warnick R, Guarnaschelli J, Sasaki A. A review of the potential Utility of Mycophenolate Mofetil as a cancer therapeutic. Journal of Cancer Research, 2014. e-Pub 2014.
44. Sumita K, Yoshino H, Sasaki M, Majd N, Kahoud ER, Takahashi H, Takeuchi K, Kuroda T, Lee S, Charest PG, Takeda K, Asara JM, Firtel RA, Anastasiou D, Sasaki AT. Degradation of activated K-Ras orthologue via K-Ras-specific lysine residues is required for cytokinesis. J Biol Chem 289(7):3950-9, 2014. e-Pub 2014. PMID: 24338482.
45. Majdzadeh N, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 68(8):1076-92, 2008. e-Pub 2008. PMID: 18498087.
46. Morrison BE, Majd NK, Zhang X, Lyles A, Bassel-Duby R, Olson EN, D'Mello SR. Neuroprotection by histone deacetylase-related protein. Molecular and Cellular Biology 26(9), 2006. e-Pub 2006. PMID: 16611996.
47. Chin PC, Majdzadeh N, D'Mello SR. Inhibition of GSK3beta is a common event in neuroprotection by different survival factors. Brain Res Mol Brain Res 137(1-2):193-201, 2005. e-Pub 2005. PMID: 15950778.
48. Johnson K, Liu L, Majd NK, Chavez C, Chin PC, Morrison BE, Wang L, Park J, Chugh P, Chen HM, D'Mello SR. Inhibition of neuronal apoptosis by the cyclin-dependent kinase inhibitor GW8510: Identification of 3' substituted indolones as a scaffold for the development of neuroprotective drugs. Journal of Neurochemistry 93(3):538-548, 2005. e-Pub 2005. PMID: 15836613.

Invited Articles

1. Ou A, Yung WK, Majd NK. Molecular Mechanisms of Treatment Resistance in Glioblastoma. International Journal of Molecular Sciences 22(1):1-24, 2020. e-Pub 2020. PMID: 33396284.
2. Majd NK, Yung WK, de Groot JF. The Promise of Poly(ADP-Ribose) Polymerase (PARP) Inhibitors in Gliomas. Journal of Immunotherapy and Precision Oncology 3(4):157-164, 2020. e-Pub 2020. PMID: 35665372.
3. Majd NK, Kamiya-Matsuoka C, de Groot JF. The path forward for anti-programmed cell death-1 therapy in gliomas. Curr Opin Neurol 32(6):864-871, 2019. e-Pub 2019. PMID: 31567548.
4. Majd NK, de Groot JF. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Expert Opin Pharmacother 20(13):1609-1624, 2019. e-Pub 2019. PMID: 31264484.

Review Articles

1. Lam, K, Kamiya Matsuoka, C, Slopis, JM, McCutcheon, IE, Majd, NK. Therapeutic Strategies for Gliomas Associated with Cancer Predisposition Syndromes. JCO Precision Oncology 8, 2024. e-Pub 2024. PMID: 38394467.
2. Robertson, IJ, Gregory, TA, Waguespack, SG, Penas-Prado, M, Majd, NK. Recent Therapeutic Advances in Pituitary Carcinoma. Journal of Immunotherapy and Precision Oncology 6(2):74-83, 2023. e-Pub 2023. PMID: 37214211.
3. Khan, S, Mittal, S, McGee, K, Alfaro-Munoz, KD, Majd, NK, Balasubramaniyan, V, de Groot, JF. Role of neutrophils and myeloid-derived suppressor cells in glioma progression and treatment resistance. International journal of molecular sciences 21(6), 2020. e-Pub 2020. PMID: 32182988.
4. Naffouje R, Grover P, Yu H, Sendilnathan A, Wolfe K, Majd N, Smith EP, Takeuchi K, Senda T, Kofuji S, Sasaki AT. Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story. Cancers (Basel) 11(9), 2019. e-Pub 2019. PMID: 31514446.
5. Majd, NK, Penas-Prado, M. Updates on Management of Adult Medulloblastoma. Current treatment options in oncology 20(8), 2019. e-Pub 2019. PMID: 31236711.
6. Majd NK, Metrus NR, Santos-Pinheiro F, Trevino CR, Fuller GN, Huse JT, Chung C, Ketonen L, Anderson MD, Penas-Prado M. RBM10 truncation in astroblastoma in a patient with history of mandibular ameloblastoma: A case report. Cancer Genet 231-232:41-45, 2019. e-Pub 2019. PMID: 30803556.
7. Majd NK, Jain SK, Murphy MC, Dugas JP, Hager F, Abdulrahman R. Total skin electron beam radiation in a pediatric patient with leukemia cutis: a case report. J Pediatr Hematol Oncol 34(7):556-8, 2012. e-Pub 2012. PMID: 23007342.
8. Majdzadeh N, Morrison BE, D'Mello SR. Class IIA HDACs in the regulation of neurodegeneration. Front Biosci 13:1072-82, 2008. e-Pub 2008. PMID: 17981613.
9. Morrison BE, Majdzadeh N, D'Mello SR. Histone deacetylases: focus on the nervous system. Cell Mol Life Sci 64(17):2258-69, 2007. e-Pub 2007. PMID: 17530170.

Editorials

1. Majd N, Weathers SP, de Groot J. Are we AKT-ually getting closer to making targeted therapy successful in breast cancer brain metastases?. Neuro Oncol 21(11):1344-1345, 2019. PMID: 31515554.

Abstracts

1. Sumrall AL, Allen JE, Bagley SJ, Brundage T, Butowski NA, Clymer J, Haggiagi A, Koschmann CJ, Kurz SC, MacDonald TJ, Majd N, Mueller S, Ramage S, Tarapore R, Thomas RP, Umemura Y, Zaky WT, Odia Y. Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Journal of Clinical Oncology 43(16). e-Pub 2025.
2. Kamiya-Matsuoka C, Weathers S, Yung WKA, Loghin M, Majd N, Brown D, Langlands J, Schwartz R, Knight S, Puduvalli V, de Groot J, O'Brien B. CTNI-78 - Evaluation of post-progression treatments after VAL-083 in recurrent and newly diagnosed GBM MGMT-unmethylated patients 25(Suupl 5):v95-v96, 2023. e-Pub 2023.
3. Majd N, Yeboa DN, Weathers S, Yuan Y, Robichaux C, Al Anssari H, Gachimova E, Loghin M, Kamiya-Matsuoka C, O'Brien B, Aaroe A, Patel C, Yung WKA, Wintermark M, Gule M, Ferguson S, Puduvalli V, de Groot J. CTNI-42 - Phase I clinical trial of peposertib plus radiation in newly diagnosed MGMT-unmethylated glioblastoma 25(Suppl 5):v84, 2023. e-Pub 2023.
4. Roth P, Papadopoulos KP, Vieito M, Yang J, Majd N, Sepulveda J, Schaff L, Moreno V, Perez-Larraya JG, Micallef S, Bellon A, Mokhtar O, Imedio ER, Piggott L, Rodriguez-Freixinos V, Rodon J. RTID-03 - A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +- radiotherapy in adults with recurrent or newly diagnosed glioblastoma 25(Suppl 5):v258-v259, 2023. e-Pub 2023.
5. Majd N, Yang L, Williford G, Alfaro-Munoz K, Pushan D, Heimberger A, Kannan K, Huse J, Bhat K, de Groot J. TMIC-58 - Alterations in glioblastoma tumor microenvironment transcriptome after treatment with pembrolizumab 25(Suppl 5):v291, 2023. e-Pub 2023.
6. Weathers S, Kamiya-Matsuoka C, Majd N, Ashu A, Thompson C, Gachimova E, Aaroe A, Patel C, Loghin M, O'Brien B, Yung WKA, Puduvalli V, de Groot J. CTIM-23 - Safety run-in results of a phase I/II study to evaluate atezolizumab in combination with cabozantinib in patients with recurrent glioblastoma 25(Suppl 5):v67, 2023. e-Pub 2023.
7. Lam K, Lin HY, Williford G, Wathoo C, Majd N. Ivosidenib off-label use for IDH mutant gliomas: The MD Anderson Cancer Center real life experience 41(suppl 16), 2023. e-Pub 2023.
8. Gregory T, Knight S, Aaroe A, O'Brien BJ, Patel CB, Weathers SS, Majd N, Puduvalli VK, Kamiya-Matsuoka C. Analysis of tumor progression among patients with glioma after COVID-19 infection 41(suppl 16), 2023. e-Pub 2023.
9. Kamiya-Matsuoka C, Majd N, Harrison R, Knight S, Langlands J, Brown D, Puduvalli V. DDDR-36. Val-083 in patients with recurrent glioblastoma treated under expanded access program 24(suppl 7):vii107, 2022. e-Pub 2022.
10. Weathers SS, Zhu H, Knafl M, Damania A, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin M, Penas Prado M, Majd NK, Yung WK, O’Brien BJ, Wistuba II, Futreal A, Wargo JA, Ajami N, Woodman SE, de Groot JF. Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation 40(Suppl 16), 2022. e-Pub 2022.
11. Bota DA, Badie B, Heimberger AB, Majd NK, Awadalla MS, Colerangle J, He S, Koppisetti S, van der Touw W, Hariri R, Pecora AL. A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM) 40(Suppl 16), 2022. e-Pub 2022.
12. Harrison RA, Majd NK, Johnson M, Urbauer D, Puduvalli V, Khasraw M. Characterization of Industry Relationships in Oncology. American Society of Clinical Oncology, 2022. e-Pub 2022.
13. Dasgupta PR, Lin H, Soomro ZA, Bornstein C, Alfaro-Munoz K, Yuan Y, De Groot JF, Majd NK. Clinical and Molecular Determinants of Survival Outcomes in Glioblastoma Patients Treated with Immune Checkpoint Inhibitors. American Academy of Neurology, 2022. e-Pub 2022.
14. Nantavithya C, Paulino AC, Liao K, Woodhouse KD, McGovern SL, Grosshans DR, MD, McAleer MF, Khatua S, Chintagumpala MM, Majd N, Zaky W, Yeboa DN. Observed‐to‐expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A surveillance, epidemiology, and end results analysis. American Cancer Society, 2021. e-Pub 2021.
15. Majd N, Majd NK, Tummala S, de Groot JF. Neurologic Toxicities of Immunotherapy. Adv Exp Med Biol(1342):417-429, 2021. e-Pub 2021. PMID: 34972978.
16. Weathers S, Knafl M, Cuentas EP, Espiridion BS, Hernandez S, Solis L, Wistuba I, Futreal A, Maru D, Kamiya-Matsuoka C, Harrison RA, Lyons L, Yun C, Darbonne WC, Loghin M, Penas-Prado M, Majd NK, Yung WKA, O’Brien BJ, Woodman S, de Groot JF. Biomarker immune correlates in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation. Society for Neuro-Oncology, 2021. e-Pub 2021.
17. Ou A, Lin H, Bornstein C, Alfaro-Munoz KD, Yuan Y, Afshar-Khargan V, Kamiya-Matsuoka C, Majd NK. The Risk and Burden of Thromboembolic and Hemorrhagic Events in Patients with Malignant Glioma Receiving Bevacizumab. Society for Neuro-Oncology, 2021. e-Pub 2021.
18. Pham LC, Gann CN, Schumacher KM, Vlassak S, Swanson T, Highsmith K, Ou A, Clarke N, Aaroe AE, Robell LJ, O’Brien BJ, Nash S, de Groot JF, Majd NK. Complete Response to Adjuvant Tepotinib in A Patient with Newly Diagnosed Disseminated Glioblastoma (GBM) Harboring MET Amplification. Society for Neuro-Oncology, 2021. e-Pub 2021.
19. Majd NK, Waguespack S, Filip J, Fu S, Penas-Prado M, Xu M, Alshawa A, Kamiya-Matsuoka C, Raza S, McCutcheon IE, Aung N. CTIM-30 - Efficacy of Pembrolizumab in Patients with Pituitary Carcinoma: results from a phase II study 22(Suppl 2):ii39-ii40, 2020. e-Pub 2020.
20. Aaroe A, Team D, Harrison RA, Majd NK, O'Brien BJ, Weathers SP, Loghin M, Kamiya-Matsuoka C, Yung WK, de Groot JF, Woodman K. COVD-30 - A snapshot of the impact of COVID-19 on patients with nervous system tumors 22(Suppl 2):ii27, 2020. e-Pub 2020.
21. Majd NK, Rizk M, Ericson S, Grzegorzewski K, Koppisetti S, Zhu J, Kang L, He S, Mahlakoiv T, van Der Touw W, Zhang X, Habboubi N, Hariri R, Hunter K, Alfaro-Munoz KD, Heimberger AB, de Groot JF, Chi L, Srour S. RTID-07 - Human Placental hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for Treatment of Recurrent Glioblastoma 22(Suppl 2):ii194-ii195, 2020. e-Pub 2020.
22. O'Brien BJ, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WK, Loghin M, Harrison RA, Majd NK, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Steino A, Lopez L, de Groot JF. CTNI-72 - Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting 22(Suppl 2):ii59, 2020. e-Pub 2020.
23. Aaroe A, Dono A, Youssef M, Alfaro-Munoz KD, Weathers SP, O'Brien BJ, Majd NK, Harrison RA, Loghin M, Soomro Z, Williford G, Fuller G, Yung WK, Yeboa D, Esquenazi Y, Ballester LY, de Groot JF, Kamiya-Matsuoka C. PATH-05 - A retrospective study of treatment strategies and outcomes in WHO grade II and III isocitrate dehydrogenase (IDH) wild-type astrocytoma 22(Suppl 2):ii164-ii165, 2020. e-Pub 2020.
24. Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu D, Sanqui E, Dervin S, Yun C, Loghin M, Penas-Prado M, Majd NK, Yung WKA, O’Brien BJ, de Groot J. CTIM-11 - Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM) 22(suppl 2):ii35, 2020. e-Pub 2020.
25. Shivaprasad A, Qasim M, Langford L, Fuller G, El-Naggar AK, Vishwanathan A, Tremont-Lukats I, Majd NK. NIMG-62 - Amphetamine-associated CNS vasculitis masquerading as tumour 22(Suppl 2):ii161-ii162, 2020. e-Pub 2020.
26. Dono A, Alfaro-Munoz KD, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Roberll L, Majd NK, de Groot JF, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY. PATH-19 - Molecular, Histologic and Clinical Characteristics of Oligodendrogliomas: A Multi-institutional Retrospective Study 22(Suppl 2):ii168, 2020. e-Pub 2020.
27. Khan S, Martinez-Ledesma E, Mittal S, Gandy K, Alfaro-Munoz KD, Majd NK, Balasubramaniyan V, de Groot JF, Khan S. STEM-09 - Intrinsic interferon signaling regulates the cell death of glioblastoma stem cells 22(Suppl 2):ii198, 2020. e-Pub 2020.
28. Weathers SP, Penas-Prado M, Banerfee PP, Bdiwi M, Shalm H, Alsuliman A, Shanley M, Long J, de Groot JF, O'Brien BJ, Majd NK, Harrison RA, Kamiya-Matsuoka C, Fuller GN, Chi L, Rao G, Lang FF, Shpall EJ, Rezvani K, Heimberger AB. A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function. Journal of Clinical Oncology 38(15):2515, 2020. e-Pub 2020.
29. Majd NK, Lin HY, Yuan Y, Alfaro-Munoz K, Hunter K, Heimberger AB, de Groot JF. Evaluation of glioblastoma tumor microenvironment after treatment with pembrolizumab. Journal of Clinical Oncology 38(15):2559, 2020. e-Pub 2020.
30. Weathers SP, Kamiya-Matsuoka C, Harrison RA, Liu DD, Dervin S, Yun C, Loghin ME, Penas-Prado M, Majd NK, Yung WKA, O'Brien BJ, de Groot JF. Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology 38(15):2511, 2020. e-Pub 2020.
31. Mittal S, Sen S, Khan S, McGee K, Alfaro-Munoz KD, Balasubramaniyan V, Majd NK, de Groot JF. Complement System and Glioblastoma: an Intricate Relationship. Society for Neuro-Oncology Conference, 2019. e-Pub 2019.
32. O'Brien B, Penas-Prado M, Kamiya-Matsuoka C, Weathers SP, Yung WK, Loghin M, Harrison R, Majd N, Bacha J, Brown D, Johnson G, Langlands J, Schwartz R, Kanekal S, Lopez L, DeGroot J. Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting. Society for Neuro-Oncology Conference 21(6):vi14-vi15, 2019. e-Pub 2019.
33. Majd N. Characterization of Adult Medulloblastoma; a retrospective review of 200 patients at MD Anderson Cancer Center. Society for Neuro-Oncology Conference, 2019. e-Pub 2019.
34. Majd N, Park S, Martinez de Kraatz M, Balasubramaniyan V, Sandeep M, Hu J, Paik J, de Groot J. MEK inhibitors for treatment of Oligodendroglioma. American Association of Cancer Research, 2019. e-Pub 2019.
35. Alfaro-Munoz K, Hallatt G, Trevino C, Majd N, Sookprasong J, Shay M, Weathers S, de Groot J, Lari B, Yu E, Jin J, Futreal A, Ravi V. Facilitating Clinical Research Through Enabling Early Exploratory Analytics. HealthCon, 2019. e-Pub 2019.
36. Mastall M, Majd N, Hess K, Fuller G, Gule-Monroe M, Huse J, Khatua S, Rao G, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M. Characterization of adult medulloblastoma patients at recurrence: retrospective review of the MD Anderson Cancer Center Experience. Society for Neuro-Oncology, 2018. e-Pub 2018.
37. Metrus NR, Daher A, Harrison RA, Majd N, Maraka. Analysis of Challenges to Accrual in Clinical Trials for Newly Diagnosed Glioblastoma. Society for Neuro-Oncology, 2018. e-Pub 2018.
38. Hamoud D, Majd N, Kleiman A. Bing Neel Syndrome: Rare Complication of Rare Disease. American Neurological Association, 2018. e-Pub 2018.
39. Mastall M, Majd N, Fuller G, Hess K, GuleMonroe M, Huse J, Khatua S, Rao G, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, Suki D, Alfaro K, Weathers S, Harrison R, de Groot J, Penas-Prado M. Adult Medulloblastoma: analysis of use of chemotherapy in clinical practice. European Association of Neuro-Oncology, 2018. e-Pub 2018.
40. Majd N, Han D, Sasaki M, Yoshino H, Chaudhary R, Warnick R, Steckl A, Sasaki A. Development of nanofiber-based controlled local drug delivery as a novel adjuvant modality for treatment of glioblastoma. Society for Neuro-Oncology, 2017. e-Pub 2017.
41. Davalos L, Quinlan J, Baba-Ahmed N, Majd N. Acute Heroin Related Neuropathy as a Result of Nerve compression due to Muscle Inflammation and Rhabodymyolysis; A Report of Two Cases. University of Cincinnati Neuroscience Institute Research Day, 2017. e-Pub 2017.
42. Randhawa J, Yoshino H, Kobayashi T, Kofuji S, Finley K, Majd N, Malhotra A, Wise-Draper T, Yamasaki T, Shibuya S, Ogawa O, Okumura K, Sasaki A. Dynamic role of GTP-energy metabolism in metastasis of renal cell carcinomas: Prognosis and therapeutic applications. American Society of Clinical Oncology, 2016. e-Pub 2016.
43. Neil E, Majd N, Morris J, Karim N, Molano J, Colapietro P, Curry R. Concurrence of gliomas in patients with multiple sclerosis; case report and literature review. Society for Neuro-Oncology, 2014. e-Pub 2014.
44. Majd N, Neil E, Warnick R, Tew J, Hagen M, Curry R. Recurrent aseptic meningitis in brain tumor patients; a novel perspective. Society for Neuro-Oncology, 2014. e-Pub 2014.
45. Majd N, Sumita K, Yoshino H, Chen D, Sasaki A. A novel therapeutic target for treatment of malignant brain tumors. American Academy of Neurology, 2014. e-Pub 2014.
46. Majd N, Xiao L, Demopoulos A, Chari A. CNS involvement in multiple myeloma patients in the era of novel therapies. American Academy of Neurology, 2013. e-Pub 2013.
47. Kushner T, Majd N, Siegel R, Wong S, Liverant M, Gonzales S. Blood urea nitrogen as a predictor of development of Post-Endoscopic Retrograde Cholangiopancreatography pancreatitis: a case-control study. Digestive Disease Week, 2012. e-Pub 2012.
48. Majd N, Sood V, Parapudi S, Dissanaike S. Hypokalaemia due to an aldosterone secreting adrenal adenoma- a case report. 23rd Annual Student Research Week – Texas Tech Univ, 2011. e-Pub 2011.
49. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. 20th Annual Student Research Week – Texas Tech Univ. Health Sciences Center, 2008. e-Pub 2008.
50. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Society for Neuroscience, 2007. e-Pub 2007.
51. Majdzadeh NK, Wang L, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. Role of HDAC4 in regulation of neuronal survival. Society for Neuroscience, 2006. e-Pub 2006.
52. Majdzadeh NK, Morrison BE, Bassel-Duby R, Olson EN, D'Mello SR. Role of HDAC4 and 5 in neuronal survival. Society for Neuroscience, 2004. e-Pub 2004.
53. Majdzadeh NK, Dieckman G. Characterization of carbon nanotubes. Biology and Chemistry Student Spring Symposium, Univ. of Texas at Dallas, 2003. e-Pub 2003.
54. Majd N, Kamiya-Matsuoka C, Yuan Y, Gachimova E, Wathoo C, Dagher S, Chen M, McCutcheon I, Slopis J, Groot JD. Window-of-opportunity trial of ulixertinib for mapk-activated lower grade gliomas in adults. SNO.
55. Majd N, Yeboa D, Wang S, Weathers SS, Yuan Y, Anssari HA, Kamiya-Matsuoka C, O'Brien BJ, Aaroe A, Patel CB, Dagher S, Wintermark M, Ferguson SD, Puduvalli VK, Liu SJ, Raleigh DR, de Groot AJF. Phase I clinical trial of peposertib plus radiotherapy in adults with newly-diagnosed MGMT-unmethylated glioblastoma. SNO.
56. Sumrall A, Allen J, Bagley S, Brundage T, Butowski N, Clymer J, Haggiagi A, Koschmann C, Kurz S, MacDonald T, Majd N, Mueller S, Ramage S, Tarapore R, Thomas R, Umemura Y, Zaky W, Odia Y. Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. ASCO.
57. Patel A, Aaroe A, Kamiya-Matsuoka C, Lin R, Majd N, O'Brien B, Patel C, Weathers SP, Puduvalli V. Dual targeting of VEGF and PD-1: A phase I/II trial of ivonescimab, a novel bispecific antibody, in recurrent glioblastoma. ASCO.

Book Chapters

1. Majd, NK, Dasgupta, P, de Groot, JF. Immunotherapy for Neuro-Oncology. In: Adv Exp Med Biol, 183-203, 2020.
2. Majd, NK, Loghin, ME. Leptomeningeal disease in solid cancers. In: Springer, 409-427, 2019.
3. Harrison RA, Majd N, Tummala S, de Groot JF. Neurologic Toxicities of Immunotherapy. In: Adv Exp Med Biol, 417-429.